IMPACT BIOMEDICAL INC. (IBO) - Dilution Analysis

10-Q filing | 107.8M shares outstanding

10-Q filing | 104.6M shares outstanding

8-K filing: DSS BioHealth Security, Inc. converted Series A Convertible Preferred Stock into 60,496,041 shares of Impact BioMedical Inc.'s common stock.

10-Q filing | 12.2M shares outstanding

10-Q filing | 12.1M shares outstanding

8-K filing: Impact BioMedical Inc. settled $8,697,142.80 of outstanding indebtedness with DSS, Inc. through the issuance of 2,415,873 shares of common stock at $3.60 per share.

10-K filing | 12.1M shares outstanding

10-Q filing | 11.5M shares outstanding

8-K filing: Impact Biomedical Inc. closed a firm commitment initial public offering of 1,500,000 shares of common stock at $3.00 per share, resulting in net proceeds of approximately $3,764,500.00 after deducting discounts, expenses allowance and expenses. ($4.5M proceeds)

S-1/A filing: This S-1/A filing details Impact BioMedical, Inc.'s initial public offering of 1,500,000 shares of common stock, with an expected price range of $3.00 to $5.00 per share, and grants the underwriters an option to purchase an additional 225,000 shares.

10-Q filing | 10.0M shares outstanding

S-1/A filing: The Registration Statement pertains to a firm commitment initial public offering and relates to the issuance and sale by the Company of shares of common stock and representative's warrants.

S-1/A filing: This is an S-1/A filing for an initial public offering of 1,500,000 shares of common stock of Impact BioMedical, Inc., with an anticipated initial public offering price between $3.00 and $5.00 per share.

10-Q filing | 10.0M shares outstanding

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock, subject to completion, with Aegis Capital Corp. as the underwriter. The company intends to offer 2,000,000 shares of common stock with an anticipated price between $3.00 and $5.00 per share.

10-K filing | 10.0M shares outstanding

S-1/A filing: This S-1/A filing, dated 2023-11-21, is for an initial public offering of 2,000,000 shares of common stock of Impact BioMedical, Inc., with an anticipated initial public offering price between $3.00 and $5.00 per share, and includes an underwriter option to purchase an additional 300,000 shares.

10-Q filing | 10.0M shares outstanding

8-K filing: Impact BioMedical, Inc. completed a share exchange agreement with DSS BioHealth Security, Inc. involving 60,496,091 shares of common stock for Series A Convertible Preferred Stock, and effected a 1-for-55 reverse stock split on October 31, 2023.

S-1/A filing: This S-1/A filing pertains to a firm commitment initial public offering of 2,000,000 shares of common stock of Impact BioMedical, Inc., with an anticipated initial public offering price between $3.00 and $5.00 per share. The company intends to apply to list its shares on the NYSE American under the symbol "[__]".

S-1 filing: This is a filing for an initial public offering of common stock, subject to completion, with Aegis Capital Corp. as the underwriter. The company is also issuing warrants to the underwriter.

10-Q filing | 3877.3M shares outstanding

S-1/A filing: This S-1/A filing describes the planned distribution of Impact BioMedical Inc. common stock to DSS, Inc. stockholders.

S-1/A filing: This is an S-1/A filing for the distribution of Impact BioMedical Inc. common stock to DSS, Inc. stockholders. DSS plans to distribute approximately 485,161,488 shares of Impact BioMedical Inc. common stock to holders of DSS common stock.

S-1/A filing: This S-1/A filing describes the planned distribution of Impact BioMedical Inc. common stock to DSS, Inc. stockholders.

S-1/A filing: This S-1/A filing describes the planned distribution of Impact BioMedical Inc. common stock to DSS, Inc. stockholders as of June 30, 2023.

S-1/A filing: This S-1/A filing pertains to the planned distribution of Impact BioMedical Inc. common stock to DSS, Inc. stockholders. DSS plans to distribute approximately 486,706,712 shares of Impact common stock to holders of DSS common stock as of June 30, 2023. Immediately prior to the Distribution, DSS will beneficially hold 3,877,282,251 of the issued and outstanding shares of common stock.

S-1/A filing: This S-1/A filing relates to the planned distribution of Impact BioMedical Inc. common stock to DSS, Inc. stockholders. DSS plans to distribute approximately 486,706,712 shares of Impact common stock to DSS common stockholders as of June 30, 2023, excluding shares held by the Chairman of the Board and his affiliates. Immediately prior to the distribution, DSS will beneficially hold 3,877,282,251 shares of Impact's common stock.

S-1/A filing: This S-1/A filing describes the planned distribution of Impact BioMedical, Inc. common stock to DSS stockholders through a distribution by DSS BioHealth Security, Inc., a wholly-owned subsidiary of DSS.

S-1/A filing: This S-1/A filing describes a planned distribution of Impact BioMedical, Inc. common stock to DSS stockholders through a wholly-owned subsidiary.

S-1/A filing: This S-1/A filing pertains to the planned distribution of Impact BioMedical, Inc. common stock to DSS stockholders. Immediately prior to the distribution, DSS will beneficially hold 100%, or 125,073,621 of the issued and outstanding shares of our Common Stock.

S-1/A filing: This S-1/A filing pertains to the planned distribution of Impact BioMedical, Inc. common stock to DSS stockholders, held by DSS through its subsidiary DSS BioHealth Security, Inc.

S-1/A filing: This S-1/A filing relates to the planned distribution of Impact BioMedical, Inc. common stock to DSS stockholders.

S-1/A filing: This S-1/A filing describes the planned distribution of Impact BioMedical, Inc. common stock to DSS stockholders through DSS BioHealth Security, Inc.

S-1/A filing: This S-1/A filing describes the planned distribution of Impact BioMedical, Inc. common stock by Document Security Systems, Inc. to its stockholders.